287 related articles for article (PubMed ID: 32444894)
1. Burden of multimorbidity and polypharmacy among cancer survivors: a population-based nested case-control study.
Keats MR; Cui Y; DeClercq V; Grandy SA; Sweeney E; Dummer TJB
Support Care Cancer; 2021 Feb; 29(2):713-723. PubMed ID: 32444894
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacy and patterns of prescription medication use among cancer survivors.
Murphy CC; Fullington HM; Alvarez CA; Betts AC; Lee SJC; Haggstrom DA; Halm EA
Cancer; 2018 Jul; 124(13):2850-2857. PubMed ID: 29645083
[TBL] [Abstract][Full Text] [Related]
3. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden.
Gallacher KI; Batty GD; McLean G; Mercer SW; Guthrie B; May CR; Langhorne P; Mair FS
BMC Med; 2014 Oct; 12():151. PubMed ID: 25280748
[TBL] [Abstract][Full Text] [Related]
4. Polypharmacy and prescription medication use in a population-based sample of adolescent and young adult cancer survivors.
Betts AC; Murphy CC; Shay LA; Balasubramanian BA; Markham C; Allicock M
J Cancer Surviv; 2023 Aug; 17(4):1149-1160. PubMed ID: 34997910
[TBL] [Abstract][Full Text] [Related]
5. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study.
Hanlon P; Nicholl BI; Jani BD; McQueenie R; Lee D; Gallacher KI; Mair FS
BMJ Open; 2018 Jan; 8(1):e018404. PubMed ID: 29332840
[TBL] [Abstract][Full Text] [Related]
6. Multimorbidity, polypharmacy and primary prevention in community-dwelling adults in Quebec: a cross-sectional study.
Nguyen TN; Ngangue P; Haggerty J; Bouhali T; Fortin M
Fam Pract; 2019 Nov; 36(6):706-712. PubMed ID: 31104072
[TBL] [Abstract][Full Text] [Related]
7. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication.
Loeppenthin K; Dalton SO; Johansen C; Andersen E; Christensen MB; Pappot H; Petersen LN; Thisted LB; Frølich A; Mortensen CE; Lassen U; Ørsted J; Bidstrup PE
Br J Cancer; 2020 Sep; 123(6):1033-1040. PubMed ID: 32632149
[TBL] [Abstract][Full Text] [Related]
8. Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study.
Holvast F; van Hattem BA; Sinnige J; Schellevis F; Taxis K; Burger H; Verhaak PFM
Fam Pract; 2017 Sep; 34(5):539-545. PubMed ID: 28369380
[TBL] [Abstract][Full Text] [Related]
9. Associations between multimorbidity and depression among breast cancer survivors within the UK Biobank cohort: a cross-sectional study.
Foster M; Niedzwiedz CL
BMC Cancer; 2021 May; 21(1):650. PubMed ID: 34058985
[TBL] [Abstract][Full Text] [Related]
10. Polypharmacy and medication fill nonadherence in a population-based sample of adolescent and young adult cancer survivors, 2008-2017.
Betts AC; Murphy CC; Shay LA; Balasubramanian BA; Markham C; Roth ME; Allicock M
J Cancer Surviv; 2023 Dec; 17(6):1688-1697. PubMed ID: 36346577
[TBL] [Abstract][Full Text] [Related]
11. Multimorbidity patterns in relation to polypharmacy and dosage frequency: a nationwide, cross-sectional study in a Japanese population.
Aoki T; Yamamoto Y; Ikenoue T; Onishi Y; Fukuhara S
Sci Rep; 2018 Feb; 8(1):3806. PubMed ID: 29491441
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in multimorbidity and polypharmacy trends: A repeated cross-sectional study of older adults in Ontario, Canada.
Maxwell CJ; Mondor L; Pefoyo Koné AJ; Hogan DB; Wodchis WP
PLoS One; 2021; 16(4):e0250567. PubMed ID: 33901232
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health.
Götze H; Köhler N; Taubenheim S; Lordick F; Mehnert A
J Geriatr Oncol; 2019 Jan; 10(1):55-59. PubMed ID: 29880406
[TBL] [Abstract][Full Text] [Related]
14. Identifying and characterizing cancer survivors in the US primary care safety net.
Hoopes M; Schmidt T; Huguet N; Winters-Stone K; Angier H; Marino M; Shannon J; DeVoe J
Cancer; 2019 Oct; 125(19):3448-3456. PubMed ID: 31174231
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Extent of Polypharmacy and its Association With Health Service Utilization Among Persons With Cancer and Multimorbidity: A Population-Based Retrospective Cohort Study in Ontario, Canada.
Dean T; Koné A; Martin L; Armstrong J; Sirois C
J Pharm Pract; 2024 Feb; 37(1):35-46. PubMed ID: 35861340
[No Abstract] [Full Text] [Related]
16. Multimorbidity and polypharmacy in hospitalized older patients: a cross-sectional study.
Zhao Y; Wang J; Zhu X; Zhang X; Zhang Y; Zhang W; Dong Y
BMC Geriatr; 2023 Jul; 23(1):423. PubMed ID: 37434147
[TBL] [Abstract][Full Text] [Related]
17. Polypharmacy and medication use by cancer history in a nationally representative group of adults in the USA, 2003-2014.
Hsu CD; Nichols HB; Lund JL
J Cancer Surviv; 2022 Jun; 16(3):659-666. PubMed ID: 34032998
[TBL] [Abstract][Full Text] [Related]
18. Polypharmacy Among Privately Insured Adults with Cerebral Palsy: A Retrospective Cohort Study.
Whitney DG; Schmidt M; Peterson MD; Haapala H
J Manag Care Spec Pharm; 2020 Sep; 26(9):1153-1161. PubMed ID: 32857655
[TBL] [Abstract][Full Text] [Related]
19. A genetic model for multimorbidity in young adults.
Malecki SL; Van Mil S; Graffi J; Breetvelt E; Corral M; Boot E; Chow EWC; Sanches M; Verma AA; Bassett AS
Genet Med; 2020 Jan; 22(1):132-141. PubMed ID: 31363180
[TBL] [Abstract][Full Text] [Related]
20. Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study.
Lopez-Rodriguez JA; Rogero-Blanco E; Aza-Pascual-Salcedo M; Lopez-Verde F; Pico-Soler V; Leiva-Fernandez F; Prados-Torres JD; Prados-Torres A; Cura-González I;
PLoS One; 2020; 15(8):e0237186. PubMed ID: 32785232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
